TMDX

TransMedics Group, Inc.

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

TransMedics Group, Inc. (TMDX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 24.9
EV / EBITDA 27.3
Rev Growth YoY 41.1%
Gross Margin 58.6%
Price Return 3M 3.4%
Price Return 12M -23.3%
Catalyst Signal 0.00
Market Cap $3.2B
TTM Revenue $727.6M
Price / Sales 4.4
ROE 31.9%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.7) C+ (2.6) C+ (2.8) B- (3.1) C+ (2.6) C+ (2.8)
2026-11-08 C+ (2.6) C+ (2.5) C+ (2.8) B- (3.0) C+ (2.6) C+ (2.7)
2026-11-01 B- (2.9) C (2.4) B- (2.9) C- (2.1) C+ (2.7) C+ (2.6)
2026-10-25 C+ (2.8) C (2.4) B- (2.9) C (2.2) C+ (2.6) C+ (2.6)
2026-10-18 C+ (2.8) C (2.4) B- (2.9) C (2.3) C+ (2.6) C+ (2.6)
Page 1 of 8
…